



## ■ INTRODUCTION

Dear Colleagues,

We are pleased to share the peer-reviewed highlights of the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Copenhagen, Denmark, from April 25 to 28, 2015.

*MD Conference Express*<sup>®</sup> provides timely, peer-reviewed highlights of high-impact presentations from the live conference, long before they are published in the academic literature, and it is a trusted education resource. The articles selected for this issue underwent a rigorous 5-step peer-review process to ensure their accuracy and provide a reliable interim information source prior to the research being vetted by the standard journal peer-review process.

The articles in this issue of *MD Conference Express* represent the most compelling topics of relevance to a broad array of practitioners and have the potential to influence clinical practice.

Among the clinical trial highlights from ECCMID is the REPRISE trial, showing that ceftazidime-avibactam effectively treated urinary tract infections caused by gram-negative bacteria. Pooled data from the RECLAIM 1 and 2 studies showed that the combination of ceftazidime-avibactam and metronidazole was noninferior to meropenem for treating complicated intra-abdominal infections.

Interferon-free strategies for treating hepatitis C and the issue of antimicrobial resistance are the focus of the feature articles. The selected update articles include a review of rapid diagnostics.

We hope that you find the articles and practical perspectives that are contained in the pages of this issue of *MD Conference Express* helpful in integrating this new information into your clinical practice. For more information, please visit [mdce.sagepub.com](http://mdce.sagepub.com).

**Sarah P. Hammond, MD**

Brigham and Women's Hospital  
Dana-Farber Cancer Institute  
Boston, Massachusetts